FDA Final Guidance: Incorporating Voluntary Patient Preference Information Over the Total Product Life Cycle
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The FDA has issued a final guidance document outlining how voluntary patient preference information (PPI) should be collected, submitted, and used throughout the total product life cycle of medical devices. The guidance establishes principles for sponsors and interested parties to follow when gathering and presenting PPI to the agency, emphasizing that patient input is a valuable and actionable component of FDA regulatory decision-making. PPI can be incorporated into multiple FDA review processes, including Investigational Device Exemption (IDE) applications, Breakthrough Device designation requests, Premarket Approval (PMA) applications, Humanitarian Device Exemption (HDE) applications, De Novo classification requests, and 510(k) premarket notifications. It may also inform administrative and enforcement decisions. The guidance further specifies how FDA will incorporate PPI into its public decision summaries, increasing transparency around how patient perspectives influence regulatory outcomes. Additionally, it provides recommendations for how PPI should be reflected in device labeling for certain categories of medical devices, directly connecting patient preference data to product documentation. This guidance is non-binding but represents the FDA's current thinking on best practices, signaling an expectation that sponsors engaging with the FDA will meaningfully consider and document patient preferences as part of their submissions across the device development and review continuum.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- FDA finalizes guidance formalizing the use of voluntary Patient Preference Information (PPI) across all stages of the medical device product life cycle
- PPI is now explicitly applicable to IDE applications, Breakthrough Device designations, PMA, HDE, De Novo, and 510(k) submissions
- FDA will include PPI in publicly available decision summaries, increasing transparency of how patient input influences regulatory outcomes
+ 3 more changes with Pro
Obligations
What this law requires
Sponsors and interested parties must collect patient preference information (PPI) using principles and concepts recommended by the FDA guidance when gathering PPI for submission to the agency
Sponsors must submit patient preference information as part of IDE applications, Breakthrough Device designation requests, PMA applications, HDE applications, De Novo classification requests, and 510(k) premarket notifications when such information is available
Sponsors must document how patient preferences have been considered and incorporated into device development and regulatory submissions throughout the total product life cycle
FDA will include patient preference information in its public decision summaries to increase transparency regarding how patient perspectives influenced regulatory outcomes
Sponsors must reflect patient preference data in device labeling for certain categories of medical devices as recommended by the FDA guidance